In the wake of the recent observations of unacceptable cardiovascular effects of selective cyclooxygenase-2 inhibitors, and mindful of the long-known gastro-intestinal irritation/damage associated with long-term consumption of NSAIDs, is this class of agent still viable as potential cancer chemopreventive intervention? Here, PTGS2 is linked to cancer.